Figure S2

A



B

	WT		KO	
LPS	-	+	-	+
M2/M1 ratio:	0.26	0.72	0.28	**2.70**



C





Figure. S2. Enhanced maturation of Runx3 KO BMDC and similar expression of TLR2 and TLR4 in WT and KO DC. **(A)** Day 11 BMDC from cultures not treated with LPS were gated as high forward scatter/$CD11c^+$ cells (R2) and assessed for expression of CD80 and MHC II. Bold lines, Runx3 KO; thin lines, WT littermates. Enhanced spontaneous maturation of the KO DC is evidenced by a larger proportion of cells with high CD80 and MHC II. **(B)** Day 7 WT and KO BMDC were grown in the presence of TGF-β (10 ng/ml) and treated (bold line) or untreated (broken line) for 4h with LPS (1μg/ml) prior to FACS analysis with anti CD11c and anti MHCII. The ratio of mature $MHCII^{high}$ (M2) DC to immature $MHCII^{low}$ (M1) is indicated above the histogram. Note that TGF-β inhibited maturation of WT BMDC as early as 4h after LPS treatment, but failed to do so in the KO BMDC **(C)** Expression of TLR2 (left) and TLR4 (right). TLR2, isolated WT and KO splenocytes were stained with anti CD11c and anti TLR2 (PE conjugated, clone 6C2, 12-9021, eBioscience) and analyzed by FACS. $CD11c^+$ DC were gated and level of TLR2 expression was measured. TLR4, day 7 WT and KO BMDC were treated for 16h with LPS (1μg/ml) before RNA extraction and RT-PCR analysis as described in Figure 3D. *TLR4* was determined at 25 and 27 cycles with the primers, F: CCTGCATAGAGGTAGTTCCTA; R: TAAGCCATGCCATGCCTTG yielding a 220bp fragment.